Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real‐world cohort
Fabian Jost‐Brinkmann(Charité - Universitätsmedizin Berlin), Raphael Mohr(Charité - Universitätsmedizin Berlin), Christoph Roderburg(Düsseldorf University Hospital), Sven H. Loosen(Düsseldorf University Hospital), Münevver Demir(Charité - Universitätsmedizin Berlin), Frank Tacke(Charité - Universitätsmedizin Berlin), Tom Luedde(Düsseldorf University Hospital), Tobias Müller(University of Cambridge), Alexander Wree(Klinikum im Friedrichshain)
Cited by 57
Related Papers
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
|Journal of Hepatology|2024|1.6k
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
|Nature|2011|1.6k
Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer
|Nature Medicine|2019|1.5k
NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinoma
|Nature Reviews Gastroenterology & Hepatology|2011|1.4k